



## PATENT APPLICATION

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q93343

Hiroyuki NAKAHIRA, et al.

Appln. No.: 10/595,125

Group Art Unit: Unknown

Confirmation No.: 3047

Examiner: Unknown

Filed: February 27, 2006

For:

**BICYCLIC PYRAZOLE DERIVATIVE** 

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

## MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

On April 28, 2006, Applicants submitted an Information Disclosure Statement in accordance with the duty of disclosure under 37 C.F.R. § 1.56. At that time, Applicants notified the U.S. Patent and Trademark Office of the documents which were listed on a PTO/SB/08 A & B (modified) form. One of the submitted references was various pages from a book entitled "Cellular Peptidases In Immune Functions and Diseases." For the Examiner's convenience and consideration, submitted herewith is a copy of the entire publication (pages 1-522). A new PTO/SB/08 A & B (modified) form is also attached.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

NAKAHIRA et al.

U.S. Appln. No.: 10/595,125

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed document is not intended as an admission that any such

document constitutes prior art against the claims of the present application. Applicant does not

waive any right to take any action that would be appropriate to antedate or otherwise remove any

listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue

Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any

overpayments to said Deposit Account.

Respectfully submitted,

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: May 10, 2006

2

Complete if Known

Q93343

Substitute for Form 1449 A & B/PTO

INFORMATION DISCUSSIVE STATEMENT BY APPLICANT

Sheet

Application Number 10/595,125

Confirmation Number 3047

Filing Date February 27, 2006

First Named Inventor Hiroyuki NAKAHIRA

Art Unit Unknown

Examiner Name Unknown

Attorney Docket Number

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite	Document Number		Publication Date			
	No.1	Number	Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Name of Patentee or Applicant of Cited Docume		
,			_				

			F	OREIGN PA	TENT DOCUME	NTS	· · · · · · · · · · · · · · · · · · ·
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date	Name of Patentee or	
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation <sup>6</sup>
-							
				+			

Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.				
		Cellular Peptidases In Immune Functions and Diseases 2, edited by Languer and Ansorge, Kluwer Academic/Plenum Publishers, (2000), (entire publication, pages 1-522).				

Examiner Signature	Date Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>3</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to indicate here if English language Translation is attached.